NVAX stock poised for volatile Monday with investors eagerly anticipating earnings report and price predictions. Deal with Sanofi to co-commercialize Covid vaccine adds optimism, but workforce reduction announcement clouds outlook. Expectations are mixed, with stock potentially soaring or facing headwinds depending on earnings performance.